Corbus Pharmaceuticals Holding
$ 10.17
4.41%
07 Aug - close price
- Market Cap 189,889,000 USD
- Current Price $ 10.17
- High / Low $ 10.23 / 9.74
- Stock P/E N/A
- Book Value 7.12
- EPS -6.37
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.53 %
- ROE -0.96 %
- 52 Week High 20.56
- 52 Week Low 7.12
About
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. The company is headquartered in Norwood, Massachusetts.
Analyst Target Price
$34.60
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-12 | 2026-03-09 | 2025-11-12 | 2025-08-05 | 2025-05-06 | 2025-03-11 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-03-12 | 2023-11-07 |
| Reported EPS | -1.81 | -1.23 | -1.25 | -1.9 | -1.44 | -1.39 | -0.78 | -1.15 | -0.9 | -0.83 | -1.81 | -2.27 |
| Estimated EPS | -1.3 | -1.22 | -1.576 | -1.71 | -1.33 | -1.07 | -1.2589 | -0.95 | -1.19 | -1.09 | -2.36 | -2.06 |
| Surprise | -0.51 | -0.01 | 0.326 | -0.19 | -0.11 | -0.32 | 0.4789 | -0.2 | 0.29 | 0.26 | 0.55 | -0.21 |
| Surprise Percentage | -39.2308% | -0.8197% | 20.6853% | -11.1111% | -8.2707% | -29.9065% | 38.0411% | -21.0526% | 24.3697% | 23.8532% | 23.3051% | -10.1942% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRBP
2026-08-08 05:40:46
Wall Street Zen has downgraded Corbus Pharmaceuticals (NASDAQ:CRBP) to a "strong sell" rating, despite a broader analyst consensus of "Moderate Buy." This comes after the company reported a quarterly EPS of -$1.81, missing analyst estimates, and saw mixed insider activity with both purchases and sales of shares. The company's stock, which has surged 342% year-to-date, opened at $10.17 and analysts expect a full-year loss of $4.87 per share.
2026-08-08 03:40:46
Corbus Pharmaceuticals Holdings Inc (CRBP) has an earnings forecast score of 9.00 and an average price target of $39.00 from analysts. The stock is rated as a "Strong Buy" by 10 analysts, with a potential upside of 297.16%. The expected revenue for the next quarter is $1.67M, and the EPS is projected at -$1.05.
2026-08-07 21:40:46
Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) rallied 4.41% to $10.17 on Friday, marking its fourth consecutive day of gains. This performance outpaced the broader market, with the NASDAQ Composite Index rising 1.30% and the Dow Jones Industrial Average rising 0.28%. The strong trading day highlighted a positive trend for the company's stock.
2026-08-07 20:40:46
An affiliate of Corbus Pharmaceuticals Holdings, Inc. (CRBP) has filed a Form 144, indicating an intent to sell up to 12,000 shares of common stock through Stifel Nicolaus & Company Inc. on or after August 7, 2026. The shares, valued at an aggregate market value of $120,971.00, are linked to equity compensation in the form of Restricted Stock Units granted in early 2026. This filing ensures transparency regarding potential insider sales.
2026-08-07 19:40:46
A Corbus Pharmaceuticals Holdings, Inc. (CRBP) shareholder has filed a Form 144, indicating an intention to sell 17,000 shares of common stock through Stifel Nicolaus & Company Inc. The proposed sale, valued at $171,396.00, is slated for August 7, 2026, on Nasdaq. The shares originate from equity awards, specifically restricted stock units granted in February 2025 and January 2026.
2026-08-07 13:40:46
Oppenheimer has revised its price target for Corbus Pharmaceuticals Holdings, Inc. to $48 from $52, while reiterating an "Outperform" rating on the stock. This adjustment comes amidst other recent news for Corbus Pharmaceuticals, including earnings results and progress in its clinical trials for obesity and cancer treatments. The company focuses on developing drugs for oncology and obesity, with a pipeline including CRB-701, CRB-601, and CRB-913.
